Community Healthcare Trust

CHCT on NYSE. Community Healthcare Trust owns medical buildings and leases them to hospitals and doctors. Market value $383m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
10.1%very high

For every $100 of what the whole company costs, it produced $10.12 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
annual report to December 2025
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 87 of 100. Price score: 80 of 100. Our list needs 70 on quality and 60 on price.

$13.36 a share, at its 1-year low

Over the past year the price has ranged from $13.23 to $19.17.

Dividend: 14.0% a year

Paid every year for at least 5 years

Yields this high often come before a cut. Check the company's latest news.

Prices from Monday’s close (5 October).

Five years of cash, in billions

0.0
0.0
0.0
0.0
0.0
0.0
2021202220232024202512 monthsto Jun '26
Revenue
$91m$98m$113m$116m$121m
Operating margin
48.0%n/an/an/an/a
Debt to equity
0.580.720.791.031.25
Shares outstanding
0.03bn0.03bn0.03bn0.03bn0.03bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)5 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • Debt1.25× equity
  • Revenue growth, five yearsSlow, 9.9% a year
  • Buying back its own sharesNo, 13% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $31 million last quarter, up 7% on a year ago.
  • Profit: $2 million, after a loss of $13 million a year ago.
  • Spare cash over the past 12 months: $39 million, up from $36 million.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Debt is $560 million more than cash, up from $498 million a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$30m
December 2024$29m
March 2025$30m
June 2025$29m
September 2025$31m
December 2025$31m
March 2026$32m
June 2026$31m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$2m
December 2024$2m
March 2025$2m
June 2025-$13m
September 2025$2m
December 2025$14m
March 2026$3m
June 2026$2m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
17 February 2026
Next quarterly (estimated, 10-Q)
3 November 2026

Who owns it

2 long-term investors we follow own it, unchanged from 2 last quarter. 170 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $331,620 of shares on the open market.

  • Dupuy David H.
    CEO and President, Director
    Bought
    Date
    14 August 2026
    Shares
    10,000
    Price
    $15.13
    Value
    $151,300
  • Hensley Robert Z
    Director
    Bought
    Date
    11 August 2026
    Shares
    8,000
    Price
    $15.21
    Value
    $121,680
  • Cotman Cathrine
    Director
    Bought
    Date
    4 November 2025
    Shares
    4,000
    Price
    $14.66
    Value
    $58,640

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Feb 2026, plus the 10-Q filed 4 Aug 2026 and 3 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Changes to U.S. tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations.

    Could happen
    There have been significant changes, and continue to be ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs, creating significant uncertainty about the future relationship between the United States and other countries with respect to trade policies, treaties and tariffs. These developments, or the perception that any of them could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the United States. Any of these factors could depress economic activity and have a material adverse effect on our business, financial condition, results of operations, and the market price of our common stock.
    Read more
  • Our tenants may be subject to compliance issues and cyber-attacks associated with the protection of personal information.

    Could happen
    The use of Artificial Intelligence (“AI”) in health care continues to increase and evolve. While there currently is no Federal law governing the use of AI in health care or otherwise, several states and Federal agencies use existing regulations to govern the use of AI and enforce related privacy violations, and it is possible that governing legislation and regulations may be forthcoming given that President Trump has issued multiple AI-related Executive Orders, including an AI Action Plan on July 23, 2025 through Executive Order, “Promoting the Export of the American AI Technology Stock,” and a December 11, 2025 Executive Order, “Ensuring a National Policy Framework for Artificial Intelligence.”
    Read more
  • The Company may enter into swap agreements from time to time that may not effectively reduce its exposure to changes in interest rates.

    Could happen
    The Company may enter into swap agreements from tim e to time that may not effectively reduce its exposure to changes in interest rates. As of December 31, 2025, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, of which $75.0 million is scheduled to expire in March 2026. Upon expiration of the swaps, the underlying indebtedness will be subject to variable interest rates. To the extent the variable rate under our Credit Facility exceeds the fixed rate under our expiring swaps, our interest expense will increase. The Company may enter into additional swap agreements in the future to manage some of its exposure to interest rate volatility; however, there can be no assurance that we will be able to do so on favorable terms, or at all. Even if we are able to enter into replacement swap agreements, prevailing market conditions may result in less favorable fixed rates that those under our expiring swaps.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.